~~<i id='697FC1CD53'><strike id='697FC1CD53'><tt id='697FC1CD53'><pre id='697FC1CD53'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：comprehensive 2025-09-29 01:45:40 - browse：88

People taking notes while sitting around a meeting table — Adobe

It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Diverse clinical trials: Why aren’t we there yet?

leisure time

hotspot

focus

leisure time

hotspot

CivicaRxisconsideringamoveintochemotherapiesamiddrugshortages.AdobeWASHINGTON—Anonprofitformedbyhosp

WSS

Histogen: Failed biotech offers rare public look inside

Was Amgen transparent enough on FDA's concern on cancer drug?

Senate panel eyes new effort on drug shortages

Acelyrin, a rare IPO success, stumbles in its first big test

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

New Covid vaccine is recommended for everyone 6 months or older

focus

knowledge

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Senate panel eyes new effort on drug shortages

Walensky prepares to leave CDC — and Congress — behind

Popular nasal decongestant doesn't actually relieve congestion

Medicare proposal to cover medical devices draws a mixed reaction

FDA panel signals lack of confidence in Amgen cancer drug data

Alkermes shareholders re

Long Covid needs a new name — and a new frame

Malaria cases in Florida and Texas: Here’s what you need to know

Long Covid needs a new name — and a new frame

hotspot

Physician executives need more than on

Senate panel eyes new effort on drug shortages

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Bill would stop addiction treatment from triggering child abuse inquiry

Hospitals consider fixing cancer drug shortages on their own

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

focus

leisure time

hotspot